Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Expanded Access Treatment with LP352 for Patients with Developmental and Epileptic Encephalopathies (DEEs) Who Successfully Completed an LP352 Clinical Trial (Intermediate-Size EAP)

NCT06149663 is registered in ClinicalTrials.gov with Longboard Pharmaceuticals as lead sponsor.

NCT NCT06149663
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06149663 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Expanded Access Treatment with LP352 for Patients with Developmental and Epileptic Encephalopathies (DEEs) Who Successfully Completed an LP352 Clinical Trial (Intermediate-Size EAP)
Lead sponsor
Longboard Pharmaceuticals
Phase
Expanded access
Overall status
Available
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

developmental and epileptic encephalopathies, dravet syndrome, lennox gastaut syndrome